Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.7265
-0.0136 (-1.84%)
May 13, 2025, 4:00 PM - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
Dysregulated Transcription Therapeutics
6.29M

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
United States
6.29M